comparemela.com

Latest Breaking News On - Joshua richter - Page 1 : comparemela.com

Dr Richter on Proactive Toxicity Management With Bispecific Antibodies in Myeloma

Joshua Richter, MD, discusses the role of bispecific antibody therapy in myeloma and expands on toxicity management for these agents.

Joshua richterTisch cancer instituteBlavatnik family chelsea medical centerDivision of hematologyMedical oncologyMultiple myelomaMount sinai

A Whole Different Ballgame for Myeloma Treatment

The BCMA protein has become the primary target for treating multiple myeloma, resulting in longer survival and more manageable side effects.

Baton rougeUnited statesTrabuco canyonNew yorkBeth israel medical centerDavid aviganNisha josephCollin richie trena robertsonJoshua richterJackie ceja cindy brownCindy brownTrena robertsonKrina patelLos angelesSouthern universityDrug administration

FDA Confirms Decision to Withdraw Melphalan Flufenamide Approval in Multiple Myeloma

The FDA has determined that sufficient criteria have been met to withdraw the approval for melphalan flufenamide in patients with multiple myeloma.

New yorkUnited statesJoshua richterFredrik schjesvoldPeter marksOncopeptide pepaxtiTisch cancer instituteEuropean commissionChelsea medical center at mount sinaiDivision of hematologyDrug administrationOncologic drugs advisory committeeEuropean unionBiologics evaluationFederal registerOrange book

ASH 2023: Multiple Myeloma s Shifting Landscape: Trials and Clinical Perspectives

Health care professionals review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) multiple myeloma revelations, spotlighting transformative trials, groundbreaking translational research, and clinical perspectives that illuminate the evolving treatment landscape.

United statesRafat abonourJoshua richterPeer exchangeFaith daviesAmrita krishnanAfrican americanMultiple myelomaMyeloma treatmentNewly diagnosed patientsMrd negative remissionTherapeutic goalsToxicity managementIndividualized approachQuadruplet therapyFrailty assessments

Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

Experts review groundbreaking insights from review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) and discuss the paradigm shift in myeloma frontline treatments, exploring quads, bispecifics, and the dynamic evolution of therapeutic approaches.

Joshua richterRafat abonourPeer exchangeFaith daviesAmrita krishnanMultiple myelomaMyeloma treatmentNewly diagnosed patientsMrd negative remissionTherapeutic goalsToxicity managementIndividualized approachQuadruplet therapyFrailty assessmentsClinical trialsTreatment regimens

vimarsana © 2020. All Rights Reserved.